Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Pancreatic Neoplasms 677Carcinoma, Non-Small-Cell Lung 324Neoplasms 168Breast Neoplasms 163Urinary Bladder Neoplasms 157Lung Neoplasms 157Neoplasm Metastasis 139Cholangiocarcinoma 111Ovarian Neoplasms 106Biliary Tract Neoplasms 91Lymphoma, Large B-Cell, Diffuse 73Nasopharyngeal Carcinoma 70Lymphoma 66Sarcoma 63Recurrence 62Gallbladder Neoplasms 60Carcinoma, Transitional Cell 55Triple Negative Breast Neoplasms 54Hodgkin Disease 52Colorectal Neoplasms 49Fallopian Tube Neoplasms 48Lymphoma, Non-Hodgkin 47Adenocarcinoma 45Bile Duct Neoplasms 40Carcinoma, Ovarian Epithelial 31Non-Muscle Invasive Bladder Neoplasms 30Uterine Cervical Neoplasms 28Carcinoma 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma of Lung 27

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Paclitaxel 2Doxorubicin 2Bevacizumab 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1nilotinib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Disease Progression × Gemcitabine × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT07049055 2026-02-27

Carolyn-USA

Engeneic Pty Limited

Phase 1/2 Recruiting
144 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Disease Progression

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

University of Maryland, Baltimore

Phase 2 Withdrawn
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT00102414 2006-11-14

Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

AGO Study Group

Phase 3 Completed
356 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡